Generic Drugmakers’ Use of Premature Patent Notices Pushes FDA to Take Action

Drug Industry Daily
Efforts by generic drugmakers to initiate patent litigation early by sending premature Paragraph IV certification notices to innovators are prompting the FDA to crack down on the practice, though it’s not yet clear what actions the agency intends to take.

To View This Article:


Subscribe To Drug Industry Daily